Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
Annexon Inc ANNX
$5.10
▼ -3.32%
($-0.18)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$5.37
Prev Close
$5.27
Day Range
$5.03 – $5.40
52W Range
$2.03 – $7.18
Market Cap
$834.78M
Beta
1.18
EPS (TTM)
$-1.20
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-07-24 |
| Shares Out. | 163,840,000 |
| Website | annexonbio.com/ ↗ |
| Phone | 16508225500 |
| Employees | 93 |
| Net Income | -$44.1M |
| Free Cash Flow | -$183.2M |
| Total Assets | $262.9M |
| Total Liabilities | $58.4M |
| Equity | $204.5M |
About Annexon Inc
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Annexon Inc is a publicly traded company under the ticker symbol ANNX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)